1. Home
  2. Primary Antibodies

Search Result - Primary Antibodies

  • anti-CD15 antibody [MEM-158] (PE)
  • Cat. No: ARG54271 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-158 reacts with CD15, a cell membrane molecule 3-fucosyl-N-acetyllactosamine (3-FAL) strongly expressed on granulocytes, monocytes, macrophages, mast cells; it is also present on Langerhans cells and some myeloid precursors cells.
    HLDA VI; WS Code AS A053
  • Conjugation: PE
  • anti-CD15 antibody [MEM-158] (PerCP)
  • Cat. No: ARG54272 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-158 reacts with CD15, a cell membrane molecule 3-fucosyl-N-acetyllactosamine (3-FAL) strongly expressed on granulocytes, monocytes, macrophages, mast cells; it is also present on Langerhans cells and some myeloid precursors cells.
    HLDA VI; WS Code AS A053
  • Conjugation: PerCP
  • anti-CD11b antibody [MEM-174] (APC)
  • Cat. No: ARG54273 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-174 recognizes CD11b antigen (Mac-1 alpha), a 165-170 kDa type I transmembrane protein mainly expressed on monocytes, granulocytes and NK-cells. The CD11b mediates neutrophil and monocyte interactions with stimulated endothelium.
    HLDA VI; WS Code BP 310
    HLDA VI; WS Code M 18
  • Conjugation: APC
  • anti-CD7 antibody [MEM-186] (PerCP)
  • Cat. No: ARG54275 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-186 reacts with CD7, a 40 kD type I transmembrane glycoprotein expressed on peripheral blood T lymphocytes, NK-cells, hematopoietic progenitors, monocytes (weakly) and also on acute lymphocytic leukemia.
    HLDA VI; WS Code T 6T-015
  • Conjugation: PerCP
  • anti-CD45RA antibody [MEM-56] (APC)
  • Cat. No: ARG54277 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-56 reacts with CD45RA, a 205-220 kDa single chain type I glycoprotein, variant of CD45 (CD45RA isoform). CD45RA is expressed on most of B lymphocytes, resting and native T lymphocytes, medullar thymocytes and monocytes.
    HLDA IV; WS Code NL 907
  • Conjugation: APC
  • anti-CD45RA antibody [MEM-56] (PerCP)
  • Cat. No: ARG54279 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-56 reacts with CD45RA, a 205-220 kDa single chain type I glycoprotein, variant of CD45 (CD45RA isoform). CD45RA is expressed on most of B lymphocytes, resting and native T lymphocytes, medullar thymocytes and monocytes.
    HLDA IV; WS Code NL 907
  • Conjugation: PerCP
  • anti-CD10 antibody [MEM-78] (APC)
  • Cat. No: ARG54281 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-78 reacts with CD10 antigen (CALLA - Common acute lymphatic leukemia antigen), a 100 kDa type II integral membrane protein.
    HLDA IV; WS Code B 506
    HLDA V; WS Code B CD10.4
  • Conjugation: APC
  • anti-CD10 antibody [MEM-78] (PerCP)
  • Cat. No: ARG54282 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-78 reacts with CD10 antigen (CALLA - Common acute lymphatic leukemia antigen), a 100 kDa type II integral membrane protein.
    HLDA IV; WS Code B 506
    HLDA V; WS Code B CD10.4
  • Conjugation: PerCP
  • anti-CD148 / DEP1 antibody [MEM-CD148 / 05] (PE)
  • Cat. No: ARG54284 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone MEM-CD148/05 recognizes CD148, a highly glycosylated up to 250 kDa receptor-like protein tyrosin phosphatase expressed mainly in lymphocytes, myeloid cells and epithelial cells.
  • Conjugation: PE
  • anti-CD305 / LAIR1 antibody [NKTA255] (PE)
  • Cat. No: ARG54288 　(Mouse mAb)
  • Reactivity: Hu
  • Application: FACS
  • Specificity: The clone NKTA255 recognizes CD305 / LAIR1, a 40 kDa type I transmembrane glycoprotein expressed on NK, T, and B cells, monocytes, dendritic cells, eosinophils, basophils, mast cells, CD34+ hematopoietic progenitor cells and thymocytes.
  • Conjugation: PE
arigo nuts about antibodies
© 2014-2024, arigo Biolaboratories Corp., All rights reserved